Want to see NVCR full AI Analyst Report?
NVCR Stock Chart & Stats
$12.83
-$0.69(-2.38%)
At close: 4:00 PM EST
$12.83
-$0.69(-2.38%)
Day’s Range― - ―
52-Week Range$9.82 - $18.92
Previous CloseN/A
Volume205.01K
Average Volume (3M)1.55M
Market Cap
$1.80B
Enterprise Value$1.04K
Total Cash (Recent Filing)$440.56M
Total Debt (Recent Filing)$233.42M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Oct 22, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding115,820,940
10 Day Avg. Volume1,340,727
30 Day Avg. Volume1,550,999
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.50Price Target Upside98.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.57
Revenue Forecast (FY)$708.73M
Bulls Say, Bears Say
Bulls Say
High And Expanding Gross MarginsSustained mid‑70s gross margins reflect a durable margin structure driven by device plus consumable economics and manufacturing improvements. High gross margins create operating leverage as revenue scales, supporting a path to sustained adjusted EBITDA breakeven and reinvestment in launches.
Recurring Revenue From Patient‑based Model And Active Patient GrowthRevenue tied to ongoing patient therapy (consumables and service) produces predictable, recurring top‑line streams. Mid‑teens revenue growth and rising active patients indicate structural demand expansion, improving visibility and scalability for margins as more patients remain on therapy.
Regulatory Approvals And Early Commercial Launches Broaden Addressable MarketA CE Mark for pancreatic cancer and early adoption signals materially expand clinical indications and geographic reach. New approved indications diversify revenue sources, increase patient pool long‑term, and reduce single‑indication dependency, supporting sustained commercial growth.
Bears Say
Persistent GAAP Losses And Negative Free Cash FlowDespite margin strength, ongoing operating losses and negative free cash flow mean the business is not yet self‑funding. Continued losses can erode flexibility, necessitate external financing for launches or trials, and constrain sustained investment if revenue momentum weakens.
Q2 Results Included One‑time Benefits; Durability Of Improvement UncertainPortions of margin and EBITDA improvement derived from non‑recurring items, which clouds the persistence of profitability gains. If one‑offs reverse, adjusted EBITDA and free cash flow could deteriorate, increasing execution risk for launches and clinical programs.
Reimbursement Fragmentation And Adoption HurdlesFragmented reimbursement and contracting requirements constrain broad, rapid uptake across key markets. Combined with early prescriber churn, these structural access barriers increase commercial cost to convert trials and launches into sustained patient utilization and recurring revenue.
NovoCure News
NVCR FAQ
What was NovoCure Ltd.’s price range in the past 12 months?
NovoCure Ltd. lowest stock price was $9.82 and its highest was $18.92 in the past 12 months.
What is NovoCure Ltd.’s market cap?
NovoCure Ltd.’s market cap is $1.80B.
When is NovoCure Ltd.’s upcoming earnings report date?
NovoCure Ltd.’s upcoming earnings report date is Oct 22, 2026 which is in 90 days.
How were NovoCure Ltd.’s earnings last quarter?
NovoCure Ltd. released its earnings results on Jul 23, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.332 by $0.202.
Is NovoCure Ltd. overvalued?
According to Wall Street analysts NovoCure Ltd.’s price is currently Undervalued.
Does NovoCure Ltd. pay dividends?
NovoCure Ltd. does not currently pay dividends.
What is NovoCure Ltd.’s EPS estimate?
NovoCure Ltd.’s EPS estimate is -0.25.
How many shares outstanding does NovoCure Ltd. have?
NovoCure Ltd. has 115,820,940 shares outstanding.
What happened to NovoCure Ltd.’s price movement after its last earnings report?
NovoCure Ltd. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.332. Following the earnings report the stock price went up 28.388%.
Which hedge fund is a major shareholder of NovoCure Ltd.?
Currently, no hedge funds are holding shares in NVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.50 (98.75% Upside)
$25.50 (98.75% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 38.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.91%
Trailing 12-Months
Company Description
NovoCure Ltd.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$25.50
▲(98.75% Upside)
Technical Analysis
Ownership Overview
2.74% Insiders
22.58% Mutual Funds
0.16% Other Institutional Investors
57.80% Public Companies and
Individual Investors